Skip to main content
. 2022 Feb 8;14(3):850. doi: 10.3390/cancers14030850

Figure 5.

Figure 5

Kaplan–Meier survival curves for: (A) Disease-free survival of patients with any third mutation and patients harboring KRAS mutation and/or TP53 mutations (n = 39). (B) Relapse-specific survival of patients with any third mutation and patients harboring KRAS mutation and/or TP53 mutations (n = 39). Log-rank test was used to test for significance. p-value < 0.05 indicates significance.